Results 171 to 180 of about 52,225 (202)

Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias

Investigational New Drugs, 2012
Effective inhibition of BCR-ABL tyrosine kinase activity with Imatinib represents a breakthrough in the treatment of patients with chronic myeloid leukemia (CML). However, more than 30 % of patients with CML in chronic phase do not respond adequately to Imatinib and the drug seems not to affect the quiescent pool of BCR-ABL positive leukemic stem and ...
Ziegler, P, Chahoud, T, Wilhelm, T, Pällman, N, Braig, M, Wiehle, V, Ziegler, S, Schröder, M, Meier, C, Kolodzik, A, Rarey, M, Panse, J, Hauber, J, Balabanov, S, Brümmendorf, T H   +14 more
openaire   +2 more sources

The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells

Biochemical Pharmacology, 2008
Chronic myelogenous leukemia (CML) is characterized by the presence of Bcr-Abl oncoprotein. Gleevec has been designed to treat many CML patients by specifically targeting Bcr-Abl, but resistance to it is already apparent in many cases. In CML cells, Bcr-Abl activates several signaling pathways, including the Ras-dependent pathway, in which growth ...
Yun-Bin, Ye, Jian-Yin, Lin, Qiang, Chen, Fang, Liu, Hui-Jing, Chen, Jie-Yu, Li, Wang-Qing, Liu, Christiane, Garbay, Michel, Vidal   +8 more
openaire   +2 more sources

Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells

Experimental Hematology, 2009
The recent success in treating chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI), such as imatinib mesylate (IM), has created a demand for reproducible methods to accurately assess inhibition of BCR-ABL activity within CML cells, including rare stem and progenitor cells, either in vitro or in vivo.
Ashley, Hamilton, Fatma, Alhashimi, Svetlana, Myssina, Heather G, Jorgensen, Tessa L, Holyoake   +4 more
openaire   +3 more sources

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Blood, 2005
Abstract AMN107 is a new, highly potent and selective BCR-ABL inhibitor currently in clinical development for the treatment of imatinib-resistant chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia ALL (Ph+ALL).
Andreas Hochhaus, Oliver G. Ottmann, Rüdiger Hehlmann, Peter Schuld, Leila Alland, Lydia Wunderle, Anja Binckebanck, Michael Emig, Thomas Schenk, Martin Müller, Philipp Erben, Heiko König, Thomas Ernst, Susanne Holm-Eriksen, Paul La Rosée   +14 more
openaire   +1 more source

Tyrosine kinase inhibitors in BCR/ABL positive ALL.

Journal of Clinical Oncology, 2011
6536 Background: The treatment of acute lymphocytic leukemia (ALL) represents a success for chemotherapy treatments developed in the early 70’s.
openaire   +1 more source

Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies

Journal of Clinical Oncology, 2005
3015 Background: AMN107, a novel aminopyrimidine ATP-competitive inhibitor of Bcr-Abl. AMN107, is 10- to 50-fold more potent than imatinib against Bcr-Abl expressing cell lines, and is effective against most cell lines expressing imatinib-resistant Bcr-Abl mutants.
O. Ottmann, F. Giles, B. Wassmann, A. Hochhaus, P. Rae, M. Beran, M. Albitar, L. Alland, M. Dugan, H. Kantarjian   +9 more
openaire   +1 more source

BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

Current Oncology Reports
The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.There is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort.
Jenna M, Menger, Ryan S, Sathianathen, Kathleen M, Sakamoto, Nobuko, Hijiya   +3 more
openaire   +2 more sources

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

Blood, 2000
F. Mahon, M. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, J. Goldman, J. Melo   +6 more
semanticscholar   +1 more source

Advances in BCR/ABL positive ALL

ADVANCES IN CELL AND GENE THERAPY, 2019
Netanel A. Horowitz, Jacob M. Rowe
openaire   +1 more source

Implicating the bcr/abl Gene in the Pathogenesis of Philadelphia Chromosome-Positive Human Leukemia

1991
Publisher Summary The hypothesis that the Philadelphia chromosome might have a causative role in human chronic myelogenous leukemia (CML) was validated by the discovery that the human homologue of the v -abl oncogene of Abelson murine leukemia virus (A-MuLV) mapped to chromosome 9q34, precisely the locus disrupted in the formation of the ...
G Q, Daley, Y, Ben-Neriah
openaire   +2 more sources